EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Flex-IT! Applying “Platform Trials” Methodology to Immunotherapy for Food Allergy in Research and Clinical Practice

Douglas P Mack, Julia Upton, Nandinee Patel, Paul J Turner

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2024.01.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Douglas P Mack und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Food Hypersensitivity. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an increasing trend in the management of food allergy toward active treatment using allergen immunotherapy (AIT). Although AIT is efficacious, treatment-related adverse events are common, particularly with oral immunotherapy in those with high levels of allergen-specific IgE sensitization. In clinical practice, these adverse events inevitably create challenges: clinicians and patients routinely face decisions whether to alter the dose itself, the frequency of dosing, and the pace of escalation, or indeed discontinue AIT altogether. Flexibility is therefore needed to adapt treatment, particularly in clinical practice, so that participants are "treated-to-target." For example, this may entail a significant change in the dosing protocol or even switching from one route of administration to another in response to frequent adverse events. We refer to this approach as flexible immunotherapy. However, there is little evidence to inform clinicians as to what changes to treatment are most likely to result in treatment success. Classical clinical trials rely, by necessity, on relatively rigid updosing protocols. To provide an evidence base to optimize AIT, the food allergy community should adopt adaptive platform trials, where a "master protocol" facilitates more efficient evaluation, including longer-term outcomes of multiple interventions. Within a single clinical trial, participants are able to switch between different treatment arms; interventions can be added or dropped without compromising the integrity of the trial. Developing platform trials for food AIT may initially be costly, but they represent a significant opportunity to grow the evidence base (with respect to both treatment outcomes and biomarker discovery) at scale. In addition, they could help understand longitudinal disease trajectories that are difficult to study in clinical trials for food allergy due to the time needed to demonstrate changes in efficacy. Finally, their adoption would achieve greater collaboration and consistency in approaches to proactive management of food allergy in routine clinical practice. As a community, we need to actively pursue this with funders and established research collaborations to deliver the very best outcomes for our patients and their families.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food HypersensitivityHumansDesensitization, ImmunologicFoodAllergensAdministration, OralAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

Adaptive platform trialEpicutaneous immunotherapyFood allergyImmunotherapyMaster protocolsOral immunotherapyPatient outcomesSublingual immunotherapy

Substanzen

Allergens

Autor:innen und Institutionen

  • Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
  • SickKids Food Allergy and Anaphylaxis Programme, Division of Immunology and Allergy, Department of Pediatrics, the Hospital for Sick Children, Toronto, Ontario, Canada; Temerty Faculty of Medicine, University of Toronto…
  • National Heart & Lung Institute, Imperial College London, London, United Kingdom.
  • National Heart & Lung Institute, Imperial College London, London, United Kingdom. Electronic address: p.turner@imperial.ac.uk.

Förderung

  • Medical Research Council

Zitieren

APA

Mack, D. P., Upton, J., Patel, N., & Turner, P. J. (2024). Flex-IT! Applying “Platform Trials” Methodology to Immunotherapy for Food Allergy in Research and Clinical Practice. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.01.009

Vancouver

Mack DP, Upton J, Patel N, Turner PJ. Flex-IT! Applying “Platform Trials” Methodology to Immunotherapy for Food Allergy in Research and Clinical Practice. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.01.009

BibTeX
@article{Mack2024,
  author = {Mack, Douglas P and Upton, Julia and Patel, Nandinee and Turner, Paul J},
  title = {Flex-IT! Applying “Platform Trials” Methodology to Immunotherapy for Food Allergy in Research and Clinical Practice},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2024.01.009}
}
Kostenlos starten →